Physician profile
Niraj S Doctor
NPI 1285925883
$3,921.08
in general payments reported to CMS, 2019-2025
27 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $93.34 · 2021: $271 · 2022: $545 · 2023: $907 · 2024: $862 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $634.49 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $485.96 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $456.32 | 2020-2025 | |
| Abbott Laboratories | $261.60 | 2021-2025 | Amplatzer Amulet, Assurity, Jot Dx |
| Medtronic, INC. | $239.65 | 2023-2025 | Corevalve Evolut R, Contour 3d, Symplicity G3 |
| Irhythm Technologies, INC. | $198.14 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Heartflow, INC. | $193.64 | 2025 | |
| Cvrx, INC. | $190.71 | 2022-2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $181.78 | 2025 | Pascal, Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $151.91 | 2024 | Inpefa |
| Boston Scientific Corporation | $143.90 | 2019-2020 | |
| Pfizer INC. | $138.87 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $109.88 | 2022-2025 | Amvuttra |
| Scpharmaceuticals INC. | $90.91 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.68 | 2022-2024 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $72.64 | 2022-2024 | Lokelma, Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $65.64 | 2022-2023 | Arcalyst |
| Gilead Sciences, INC. | $56.92 | 2019 | |
| Abiomed | $27.79 | 2025 | |
| Esperion Therapeutics, INC. | $23.44 | 2021 | |
| Reflow Medical INC | $20.59 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.75 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.59 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.06 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $17.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Doctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.